Octreotide treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma with cirrhosis of the liver_0.doc

 PAGE \* MERGEFORMAT 17 Octreotide treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma with cirrhosis of the liver [Abstract] Objective To evaluate the effect of octreotide combined with transcatheter arterial chemoembolization (TACE treatment of hepatocellular carcinoma complicated with liver cirrhosis the clinical effect. Methods Child-Pugh score A or B level in patients with liver cirrhosis in 55 cases of hepatocellular carcinoma. Experimental group of 24 patients, and 1 day after TACE using octreotide 0.2mg subcutaneously 2 times a day. the control group of 31 patients receiving TACE treatment. every 3 months for a second evaluation. on two groups of 6 months and 1,2 3-year survival rate were compared. Results There were no CR, 16 patients in the experimental group PR, the effective rate was 66.67%. 11 patients in the control group PR, the effective rate was 35.48%. efficiency between the two groups was significant (P lt;0.05). experimental group, 3-year survival rate was 45.83%, while the control group, 3-year survival rate was 19.35%. 3-year survival difference between the two groups was significant (P lt;0.05. experimental group, the median survival time was 31 months, control group median survival was 20 months. experimental group median TTP of 9 months in the control group for 6 months. Octreotide Side effects were mild diarrhea. Conclusion octreotide TACE treatment of hepatocellular carcinoma complicated with liver cirrhosis have a clear effect. [Keywords:] octreotide, liver cirrhosis, hepatocellular carcinoma, chemoembolization, therapeutic Abstract: Objective This article is to evaluate the effects of octreotide in combination with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma complicated with liver cirrhosis. Methods Fifty-five consecutive patients in Child-Pugh classification A and B were admitted into the 3-year trial. Twenty-four patients in the octreotide group received octre